title: Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.
abstract: As inhibitor of apoptosis (IAP) proteins can regulate additional signaling pathways beyond apoptosis, we investigated the effect of the second mitochondrial activator of caspases (Smac) mimetic BV6, which antagonizes IAP proteins, on non-apoptotic functions in glioblastoma (GBM). Here, we identify non-canonical nuclear factor-κB (NF-κB) signaling and a tumor necrosis factor-α (TNFα)/TNF receptor 1 (TNFR1) autocrine/paracrine loop as critical mediators of BV6-stimulated migration and invasion of GBM cells. In addition to GBM cell lines, BV6 triggers cell elongation, migration and invasion in primary, patient-derived GBM cells at non-toxic concentrations, which do not affect cell viability or proliferation, and also increases infiltrative tumor growth in vivo underscoring the relevance of these findings. Molecular studies reveal that BV6 causes rapid degradation of cellular IAP proteins, accumulation of NIK, processing of p100 to p52, translocation of p52 into the nucleus, increased NF-κB DNA binding and enhanced NF-κB transcriptional activity. Electrophoretic mobility shift assay supershift shows that the NF-κB DNA-binding subunits consist of p50, p52 and RelB further confirming the activation of the non-canonical NF-κB pathway. BV6-stimulated NF-κB activation leads to elevated mRNA levels of TNFα and additional NF-κB target genes involved in migration (i.e., interleukin 8, monocyte chemoattractant protein 1, CXC chemokine receptor 4) and invasion (i.e., matrix metalloproteinase-9). Importantly, inhibition of NF-κB by overexpression of dominant-negative IκBα superrepressor prevents the BV6-stimulated cell elongation, migration and invasion. Similarly, specific inhibition of non-canonical NF-κB signaling by RNA interference-mediated silencing of NIK suppresses the BV6-induced cell elongation, migration and invasion as well as upregulation of NF-κB target genes. Intriguingly, pharmacological or genetic inhibition of the BV6-stimulated TNFα autocrine/paracrine loop by the TNFα-blocking antibody Enbrel or by knockdown of TNFR1 abrogates BV6-induced cell elongation, migration and invasion. By demonstrating that the Smac mimetic BV6 at non-toxic concentrations promotes migration and invasion of GBM cells via non-canonical NF-κB signaling, our findings have important implications for the use of Smac mimetics as cancer therapeutics.
authors.affiliation: Institute for Experimental Cancer Research in Pediatrics, Goethe University, Frankfurt, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Tchoghandjian
authors.forename: C
authors.initials: C
authors.lastname: Jennewein
authors.forename: I
authors.initials: I
authors.lastname: Eckhardt
authors.forename: K
authors.initials: K
authors.lastname: Rajalingam
authors.forename: S
authors.initials: S
authors.lastname: Fulda
mesh_terms: D051017:Apoptosis Regulatory Proteins; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D000068800:Etanercept; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000737:chemistry*; D024101:Mitochondrial Proteins / Q000737:chemistry*; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000517:prevention & control; D057786:Peptidomimetics / Q000494:pharmacology*; D021122:Protein Subunits / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
chemical_list: D051017:Apoptosis Regulatory Proteins; C412403:DIABLO protein, human; D007074:Immunoglobulin G; D051034:Inhibitor of Apoptosis Proteins; D047908:Intracellular Signaling Peptides and Proteins; D024101:Mitochondrial Proteins; D016328:NF-kappa B; D057786:Peptidomimetics; D021122:Protein Subunits; D034741:RNA, Small Interfering; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept
references.citation: Nat Immunol. 2008 Dec;9(12):1371-8
references.pmid: 18997794
references.citation: Cancer Res. 2007 Dec 15;67(24):11493-8
references.pmid: 18089776
references.citation: Cancer Cell. 2010 Jan 19;17(1):53-64
references.pmid: 20129247
references.citation: Cell. 2007 Nov 16;131(4):669-81
references.pmid: 18022362
references.citation: Oncogene. 2013 Feb 21;32(8):988-97
references.pmid: 22469979
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3792-7
references.pmid: 9520446
references.citation: Nat Immunol. 2011 Jul 19;12(8):695-708
references.pmid: 21772278
references.citation: J Biol Chem. 2011 Apr 15;286(15):13282-91
references.pmid: 21339290
references.citation: Mol Cell. 2008 Jun 20;30(6):689-700
references.pmid: 18570872
references.citation: J Biol Chem. 2011 May 6;286(18):15630-40
references.pmid: 21402697
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1624-36
references.pmid: 12697889
references.citation: J Cell Mol Med. 2009 Oct;13(10):4239-56
references.pmid: 19725919
references.citation: Oncogene. 2005 Oct 20;24(46):6945-56
references.pmid: 16007147
references.citation: Science. 1997 Oct 31;278(5339):866-9
references.pmid: 9346485
references.citation: J Cell Sci. 2011 Feb 15;124(Pt 4):647-56
references.pmid: 21266470
references.citation: Cell. 2000 Jul 7;102(1):43-53
references.pmid: 10929712
references.citation: Neoplasia. 2009 Aug;11(8):743-52
references.pmid: 19649204
references.citation: J Clin Oncol. 2002 Feb 15;20(4):1063-8
references.pmid: 11844831
references.citation: Cell. 2000 Jul 7;102(1):33-42
references.pmid: 10929711
references.citation: Nat Med. 2002 Aug;8(8):808-15
references.pmid: 12118245
references.citation: Oncogene. 2009 Sep 3;28(35):3097-110
references.pmid: 19597472
references.citation: Int J Cancer. 2007 Sep 15;121(6):1190-6
references.pmid: 17520672
references.citation: Mol Cancer Ther. 2011 Oct;10(10):1867-75
references.pmid: 21859841
references.citation: EMBO J. 2012 Jan 4;31(1):14-28
references.pmid: 22117219
references.citation: Nat Cell Biol. 2008 Dec;10(12):1447-55
references.pmid: 19011619
references.citation: Clin Cancer Res. 2011 Jun 15;17(12):4019-30
references.pmid: 21525171
references.citation: Br J Cancer. 2010 Feb 16;102(4):639-44
references.pmid: 20087353
references.citation: Lab Invest. 1996 Jan;74(1):108-19
references.pmid: 8569172
references.citation: J Neurooncol. 2007 Oct;85(1):39-47
references.pmid: 17479228
references.citation: Hepatology. 2008 Aug;48(2):497-507
references.pmid: 18666224
references.citation: J Immunol. 2010 Apr 15;184(8):4497-509
references.pmid: 20231695
references.citation: Cell. 2007 Nov 16;131(4):682-93
references.pmid: 18022363
references.citation: Oncogene. 2001 Nov 22;20(53):7722-33
references.pmid: 11753650
references.citation: Oncogene. 2007 Jan 11;26(2):248-57
references.pmid: 16832350
references.citation: Nat Immunol. 2008 Dec;9(12):1364-70
references.pmid: 18997792
references.citation: Mol Cell Biol. 1994 Dec;14(12):7695-703
references.pmid: 7969113
references.citation: Cell Death Differ. 2012 Aug;19(8):1337-46
references.pmid: 22343715
references.citation: J Biol Chem. 2008 Sep 5;283(36):24295-9
references.pmid: 18621737
references.citation: Cell Death Differ. 1999 Apr;6(4):370-6
references.pmid: 10381630
references.citation: Brain Tumor Pathol. 2005;22(2):79-87
references.pmid: 18095109
references.citation: Cancer Res. 1997 Nov 1;57(21):4956-64
references.pmid: 9354463
references.citation: Am J Physiol Heart Circ Physiol. 2010 Aug;299(2):H300-9
references.pmid: 20472758
references.citation: Acta Neuropathol. 2007 Nov;114(5):443-58
references.pmid: 17805551
references.citation: Mol Cell. 2011 Jun 10;42(5):569-83
references.pmid: 21549626
references.citation: EMBO Rep. 2006 Oct;7(10):988-94
references.pmid: 17016456
references.citation: Glycoconj J. 2006 May;23(3-4):221-32
references.pmid: 16691505
references.citation: J Immunol. 2012 Mar 1;188(5):2380-6
references.pmid: 22287708
references.citation: Nat Rev Drug Discov. 2012 Feb 01;11(2):109-24
references.pmid: 22293567